Relationship Proteases - Transglutaminases

Transglutaminases catalyze the acyl-transfer reaction between a γ-carboxamide group of glutamine and the ε-amino group of lysine, which results in the formation of isopeptide bonds. Human transglutaminases possess a catalytic triad and the reaction proceeds via a reactive intermediate linked to the nucleophilic cysteine of the enzyme. The mechanism is similar to the proteolysis reaction catalyzed by thiol proteases that posses the same catalytic triad. It turned out that transglutaminases are using a similar structural architecture as papain-like thiol proteases and obviously even have an evolutionary relationship.

Also biology and physiology are closely related. E.g. the transglutaminase coagulation factor XIIIa cross-links fibrin and therefore plays an important role in blood clot formation. The serine protease thrombin (T056) activates factor XIII cleaving the activation peptide. Subsequently, plasmin (P012) degrades the fibrin clot. Therefore proteases are important tools in transglutaminase research.

Art. No.
D005 Metalloprotease-Assay-Substance
2 mg
325 €
D017 Thrombin-Assay Substance, fluorescent
10 mg
200 €
P003 Prolylendopeptidase from Myxococcus xanthus, recombinant
150 U
400 €
P009 human Pro-Glu-Plasminogen, recombinant
100 µg
450 €
P012 human Plasmin, recombinant
(from Glu-Plasminogen, activated by Urokinase)
100 µg
450 €
P014 Urokinase
1 mg
400 €
P016 Tissue Plasminogen Activator, t-PA
100 µg
400 €
T004 Plasmin substrate Tosyl-GPKpNA, chromogenic
N-(p-Tosyl)-Gly-Pro-Lys-pNA acetate
25 mg
350 €
T056 Human alpha thrombin, highly active
2x 100 U
200 €
T222 Human Alpha Thrombin, recombinant
100 NIH Units
200 €
Z020 Thrombin-Generation-Assay Substance, fluorescent
25 mg
200 €


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageSuccessful ISO9001:2015 recertification
  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy